Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of IBI363 plus bevacizumab in advanced solid tumors
CTR20253039Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI363, bevacizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by InnoCare Pharma. Started Aug 2025; status: active.
02
Drugs
IBI363bevacizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20253039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253039.